Showing results (141-150 of 283) with videos related to
Sort By:
Pageof 29
Journal of the National Cancer Institute. Monographs|January 1, 1993
In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated Taxol resistanceM Lehnert, S Emerson, W S Dalton, et al.Cancer Treatment Reports|March 1, 1984
Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group studyJ D Bonnet, R Alexanian, S E Salmon, et al.Investigational New Drugs|January 1, 1986
Phase II trial of 4'-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancerT Braich, F R Ahmann, H S Garewal, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1984
Relation of in vitro colony survival to clinical response in a prospective trial of single-agent chemotherapy for metastatic melanomaF L Meyskens, L Loescher, T E Moon, et al.Blood|December 15, 1991
Prognostic correlation of plasma cell acid phosphatase and beta-glucuronidase in multiple myeloma: a Southwest Oncology Group studyS M Saeed, D Stock-Novack, R Pohlod, et al.Nouvelle Revue Francaise D'Hematologie|January 1, 1983
[Treatment of chronic autoimmune thrombopenic purpura with intravenous immunoglobulins. Study of 18 cases]M Janvier, J P Clauvel, G Tobelem, et al.La Nouvelle Presse Medicale|May 1, 1982
[Mechanisms and prognosis of neutropenia in Felty's syndrome. 27 cases (author's transl)]O Meyer, J P Clauvel, C Dresch, et al.Blood Cells|January 1, 1981
Immunological phenotypes of human leukemias of the B-cell lineageM Seligmann, L B Vogler, J L Preud'Homme, et al.Journal of Clinical Immunology|January 1, 1989
Increased peripheral blood leukocyte cytotoxic activity in cancer patients during the continuous intravenous administration of recombinant human tumor necrosis factorP S Charnetsky, R A Greisman, S E Salmon, et al.Investigational New Drugs|January 1, 1994
Phase II study of carboplatin (CBDCA) in refractory multiple myeloma. A Southwest Oncology Group studyB Barlogie, J Crowley, S E Salmon, et al.Pageof 29